- Home
- ABVX vs LFUS Comparison
ABVX vs LFUS Comparison
Compare ABVX & LFUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVX
- LFUS
- Stock Information
- Founded
- ABVX 2013
- LFUS 1927
- Country
- ABVX France
- LFUS United States
- Employees
- ABVX N/A
- LFUS N/A
- Industry
- ABVX
- LFUS Electrical Products
- Sector
- ABVX
- LFUS Energy
- Exchange
- ABVX Nasdaq
- LFUS Nasdaq
- Market Cap
- ABVX 5.3B
- LFUS 5.7B
- IPO Year
- ABVX N/A
- LFUS N/A
- Fundamental
- Price
- ABVX $70.44
- LFUS $250.64
- Analyst Decision
- ABVX Buy
- LFUS Hold
- Analyst Count
- ABVX 7
- LFUS 3
- Target Price
- ABVX $74.86
- LFUS $234.50
- AVG Volume (30 Days)
- ABVX 3.2M
- LFUS 219.2K
- Earning Date
- ABVX 08-11-2025
- LFUS 07-30-2025
- Dividend Yield
- ABVX N/A
- LFUS 1.20%
- EPS Growth
- ABVX N/A
- LFUS N/A
- EPS
- ABVX N/A
- LFUS 4.29
- Revenue
- ABVX $11,444,012.00
- LFUS $2,264,614,000.00
- Revenue This Year
- ABVX N/A
- LFUS $6.40
- Revenue Next Year
- ABVX $41.36
- LFUS $7.76
- P/E Ratio
- ABVX N/A
- LFUS $58.42
- Revenue Growth
- ABVX 128.98
- LFUS 1.34
- 52 Week Low
- ABVX $4.77
- LFUS $142.10
- 52 Week High
- ABVX $75.51
- LFUS $275.56
- Technical
- Relative Strength Index (RSI)
- ABVX 80.00
- LFUS 55.35
- Support Level
- ABVX $68.26
- LFUS $244.51
- Resistance Level
- ABVX $73.90
- LFUS $263.68
- Average True Range (ATR)
- ABVX 3.64
- LFUS 8.00
- MACD
- ABVX -1.64
- LFUS 0.03
- Stochastic Oscillator
- ABVX 46.06
- LFUS 46.18
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
About LFUS Littelfuse Inc.
Littelfuse is a primary provider of circuit protection products (such as fuses and relays) into the transportation, industrial, telecommunications, and consumer electronics end markets. The firm is also increasing its power semiconductor business, where it predominantly serves industrial end markets and is breaking into electric vehicle charging infrastructure. Littelfuse has 17,000 global employees.